Denmark $286 Billion Healthcare Giant Novo Nordisk Files $830 Million Lawsuit in Singapore & Freezes Assets of Singapore-Based Biotech Company KBP BioSciences & Founder Huang Zhenhua for Misleading Effectiveness of Experimental Hypertension & Kidney Disease Drug (Ocedurenone), Novo Nordisk Acquired KBP BioSciences for $1.3 Billion in 2023, Novo Nordisk Stopped Clinical Trial Due to Effectiveness of Ocedurenone & Announced $800 Million Loss Impairment, Singapore International Commercial Court Approves to Freeze Assets of KBP BioSciences & Founder Huang Zhenhua
20th February 2025 | Hong Kong
Denmark healthcare giant Novo Nordisk ($286 billion market value) has filed a $830 million lawsuit & freezes assets of Singapore-based biotech Company KBP BioSciences & founder Huang Zhenhua for misleading the effectiveness of experimental hypertension & kidney disease grug (Ocedurenone). In 2023, Novo Nordisk acquired KBP BioSciences for $1.3 billion. Subsequently, Novo Nordisk stopped clinical trial due to effectiveness of ocedurenone and announced $800 million loss impairment. A Singapore International Commercial Court has approved to freeze assets of KBP BioSciences & founder Huang Zhenhua. In 2024, biotech company KBP BioSciences founder Huang Zhenhua’s wife Lai Jun has bought a Singapore bungalow near Orchard shopping district for $24 million (S$32.5 million). Huang Zhenhua founded KBP BioSciences in 2011. Both Huang Zhenhua & Lai Jun are Singapore citizens. Huang Zhenhua was born in China Shandong Province. In 2025, Denmark philanthropic foundation Novo Nordisk Foundation reported to have awarded $1.4 billion in 2024 to support around 1,800 new projects to improve health & sustainability (in society & the planet). Novo Nordisk Foundation was founded in 1924 in Denmark with philanthropic objectives. Acquisition Announcement (16/10/23): “Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars. Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that is currently being examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease (CKD). Uncontrolled hypertension is when a person’s blood pressure remains high despite taking two or more blood pressure-lowering treatments. To date, ocedurenone has been investigated in nine clinical trials including the BLOCK-CKD Phase 2b trial. The BLOCK-CKD trial met its primary endpoint with ocedurenone demonstrating a clinically meaningful and statistically significant improvement in systolic blood pressure (SBP) from baseline to day 84 in patients with stage 3b/4 CKD and uncontrolled hypertension. There were no reports of severe hyperkalemia or acute kidney injury with ocedurenone in the trial. The CLARION-CKD phase 3 trial has been initiated in the US, Europe and Asia with the first patient dosed at the end of 2021 and will continue as planned with a total of more than 600 patients expected to be randomised by more than 150 sites. Novo Nordisk expects to initiate phase 3 trials in additional cardiovascular and kidney disease indications in the coming years, aiming to maximise the full potential of ocedurenone. The closing of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions and is expected to happen before the end of 2023. The transaction will not impact Novo Nordisk’s previously communicated operating profit outlook for 2023 or the ongoing share buy-back programme. Novo Nordisk will fund the acquisition from financial reserves.”
“ Denmark $286 Billion Healthcare Giant Novo Nordisk Files $830 Million Lawsuit in Singapore & Freezes Assets of Singapore-Based Biotech Company KBP BioSciences & Founder Huang Zhenhua for Misleading Effectiveness of Experimental Hypertension & Kidney Disease Drug (Ocedurenone), Novo Nordisk Acquired KBP BioSciences for $1.3 Billion in 2023, Novo Nordisk Stopped Clinical Trial Due to Effectiveness of Ocedurenone & Announced $800 Million Loss Impairment, Singapore International Commercial Court Approves to Freeze Assets of KBP BioSciences & Founder Huang Zhenhua “
Novo Nordisk – Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries.
KBP Biosciences – KBP Biosciences is a global, clinical-stage biotechnology company, headquartered in Singapore, focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal disease with large unmet medical needs. KBP Biosciences is engaged by its partner in developing a treatment for patients with uncontrolled hypertension and stage 3b/4 CKD. CLARION-CKD, a global Phase 3 clinical trial, is currently being conducted and expected to complete by the end of 2024.
Biotech Company KBP BioSciences Founder Huang Zhenhua Wife Lai Jun Buys Singapore Bungalow Near Orchard Shopping District for $24 Million, Huang Zhenhua Founded KBP BioSciences in 2011, Both Huang Zhenhua & Lai Jun are Singapore Citizens, Huang Zhenhua was Born in China Shandong
7th June 2024 – Biotech company KBP BioSciences founder Huang Zhenhua’s wife Lai Jun has bought a Singapore bungalow near Orchard shopping district for $24 million (S$32.5 million). Huang Zhenhua founded KBP BioSciences in 2011. Both Huang Zhenhua & Lai Jun are Singapore citizens. Huang Zhenhua was born in China Shandong Province.
Sign Up / Register
Caproasia Users
- Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2025 Investment Day
- March - Hong Kong
- March - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
